Ingelheim, Germany (ots/PRNewswire) - - 1 in 10 Women Experience Distress Associated With the Most Common Form of Female Sexual Dysfunction, yet the Condition Remains Largely Under-Recognised and Under-Diagnosed - For non-US media only Results from the PRESIDE*(1) survey, the largest study assessing the prevalence of female sexual problems, show that low sexual desire ...
Beijing (ots/PRNewswire) - New results from the landmark ONTARGET(R) Trial show that, in Asian patients at high risk of cardiovascular disease (CVD), telmisartan (MICARDIS(R)) 80mg is as effective as, and significantly better tolerated than, ramipril 10mg in reducing the risk of cardiovascular death, heart attack, ...
Ingelheim, Germany (ots/PRNewswire) - - BI 6727, a Highly Potent and Selective Plk1 inhibitor, Represents Latest Advance in Company's Plk1 Programme - For non-US Healthcare Media Boehringer Ingelheim's most promising new cell cycle kinase inhibitor and potentially first-in-class compound, BI 6727, has shown ...
Ingelheim and Biberach, Germany (ots/PRNewswire) - - Boehringer Ingelheim Oncology Pipeline Advances: Two Leading Compounds are Entering Phase III Trials - Boehringer Ingelheim's Investigational Compound in Development for the Treatment of Pre-Menopausal Women Suffering From Hypoactive Sexual Desire Disorder (HSDD) ...
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A., Canada, and Japan - Favourable Safety and Efficacy Profile of Actilyse(R) Confirmed by ECASS 3 Study Investigating Treatment in an Extended Time Window up to 4.5 Hours After Symptom Onset First results from ECASS 3 (European Cooperative ...
Munich, Germany (ots/PRNewswire) - - TRANSCEND(R), Parallel Trial to ONTARGET(R), Confirms Long-Term Protective Benefits and Excellent Tolerability Profile of Telmisartan 80mg(1) on Top of Current Best Standard of Care MUNICH, Germany, August 31 /PRNewswire/ -- - For non-US Healthcare Media The results of the ...
Berlin (ots/PRNewswire) - - For non-US Healthcare Media and non-UK Healthcare Media - New Studies Show Benefits of MICARDIS(R) (Telmisartan) in Combination With Amlodipine and Hydrochlorothiazide The results of two new studies of MICARDIS(R) (telmisartan) in free combination with amlodipine or fixed combination with hydrochlorothiazide (HCTZ) 25 mg confirm that a ...
Ingelheim, Germany (ots/PRNewswire) - - First Ever Study to Demonstrate Efficacy of Pramipexole in Treating RLS-Associated Limb Pain - For Healthcare Media Outside the U.S.A. A new study demonstrating that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce RLS-associated limb pain in patients with ...
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Media - Boehringer Ingelheim Announces Commitment to Progressing Science in This Area of Unmet Medical Need With the 'Bouquet' Studies. Data announced at this week's American College of Obstetricians and Gynecologists (ACOG) annual clinical meeting suggest that up ...
Ingelheim, Germany (ots/PRNewswire) - The science of sexual desire No doubt you've written about it before: Sex - an ever-present topic in newspapers and magazines. Yet, despite the genuine interest in sex, little focus is given to the science behind it and even less so when it comes to female sexual dysfunction, the most common type being Hypoactive Sexual Desire Disorder (HSDD). Up to one in ten women suffer from HSDD - ...
Ingelheim, Germany (ots/PRNewswire) - - For non-US Healthcare Media - Abstract # 163O. von Pawel. Proffered Papers 6 - Advanced NSCLC - Latest Phase II Data for Boehringer Ingelheim's New Cancer Drug in Development Presented Monotherapy treatment with the triple angiokinase inhibitor(1) BIBF 1120 (planned tradename ...
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A. - Studies Demonstrate Positive and Rapid Impact of Pramipexole on the Core Symptoms of Restless Legs Syndrome and Sleep Disturbance A new study has shown that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce sleep ...
Ingelheim, Germany (ots/PRNewswire) - - For Medical Media, Outside the US Only Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation of the new powerful strength of their fixed dose combination antihypertensive drug MicardisPlus(R) 80/25 in all 27 EU member states. It ...
Ingelheim, Germany (ots/PRNewswire) - - Results of 25,620 Patient Study ONTARGET(R) (ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial) Presented Today at the 57th Annual Scientific Session of the American College of Cardiology(1) - For Non-US Healthcare Media The results of the ...
Madrid, Spain (ots/PRNewswire) - - For Non-U.S. Media New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with Norvir (ritonavir), provides a superior and durable treatment response for up to three years in treatment- experienced HIV patients versus ...
Ingelheim, Germany (ots/PRNewswire) - - New Data on BIBW 2992(i), a Potent, Irreversible, Second-Generation Oral Signal Transduction Inhibitor Provides Glimpse of Next Chapter in Lung Cancer Care - For Non-US Media Boehringer Ingelheim announced today from the 12th World Conference on Lung Cancer (WCLC) that the company plans to commence Phase III ...
Ingelheim, Germany (ots/PRNewswire) - Constipation is a condition that we are all familiar with, however, according to new international research from Dulcolax(R), constipation actually affects much more than just bowel movements and can have a severely detrimental impact on people's quality of life, in some cases comparable to that experienced by people suffering from more serious ailments. The Dulcolax(R) survey ...
Sydney, Australia (ots/PRNewswire) - New data from two new studies of Viramune(R) (nevirapine) were presented at the 4th International AIDS Society (IAS) in Sydney, Australia. Results from an extended three-year follow-up analysis of the 2NN study demonstrated that HIV-positive patients taking ...
Ingelheim, Germany (ots/PRNewswire) - - Trial to compare newest protease inhibitors in treatment-experienced patients with resistance to more than one PI Boehringer Ingelheim GmbH announced today that enrollment of the POTENT study will begin in August 2007. POTENT will compare the efficacy and safety ...
Sydney, Australia (ots/PRNewswire) - Recent launches of new protease inhibitors and the anticipated availability of new antiretroviral drug classes have increased the therapeutic options available to treatment-experienced HIV-positive patients, and made achieving an undetectable viral load a realistic goal ...
Sydney, Australia (ots/PRNewswire) - - Panelists Available For Interviews - For Immediate Release: Webcast Will Be Available At: Http://Link.Viostream.Com/?A02deceb-Ecf4-4d9f-9118-F5f60faef629 Women Living Positive, a roundtable discussion at the IAS congress in Sydney, featured the ...
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The results from ...
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media - Results From Two Large, Multinational, Practice-Based Observational Studies in Blood Pressure New data announced today at the Annual European Society of Hypertension (ESH) show that measuring blood pressure in a doctor's office alone does ...
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim GmbH announced today that it has begun to enroll patients in the SPRING study. The SPRING study will be one of the largest racially and gender diverse international studies of highly treatment-experienced HIV-1 infected patients. The trial ...
Ingelheim Am Rhein, Germany (ots/PRNewswire) - - Studies Reinforce the Benefits of Pramipexole From Daytime Symptom Control, Including Afternoon and Early Evening Onset - For Healthcare Media Outside the U.S.A. New data demonstrate that pramipexole (Mirapexin(R)/Sifrol(R)) is also efficacious and ...
Ingelheim, Germany (ots/PRNewswire) - - Trial to Compare Efficacy and Safety of Viramune(R) (Nevirapine) Versus Atazanavir/Ritonavir in Treatment-Naive Patients Boehringer Ingelheim GmbH announced today that it has initiated and begun enrollment of patients in the ArTEN trial, which will compare the efficacy and safety of Viramune(R) (nevirapine), ...
Ingelheim, Germany (ots/PRNewswire) - Long-term data from the Nevirapine/Efavirenz/Abacavir (NEFA) study demonstrate that patients who switched from a protease inhibitor-based regimen to a non-nucleoside reverse transcriptase inhibitor-based regimen containing Viramune(R) (nevirapine) or efavirenz achieved comparable efficacy and safety to their previous regimen ...
Glasgow, Scotland, November 15 (ots/PRNewswire) - - New Sub-analyses Provide Insight into Treatment Benefits New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with ritonavir (tipranavir/r) as part of combination antiretroviral therapy, continued to ...
Ingelheim, Germany, November 10 (ots/PRNewswire) - - Millions of People Worldwide Living With RLS to Benefit as Treatment Becomes Globally Available Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the ...
Kyoto, Japan (ots/PRNewswire) - - Further Therapeutic Potential of Pramipexole to be Investigated in New Disease-Modification Trial - For non-US Healthcare Media New data presented today from a meta-analysis* of nearly 1,300 Parkinson's disease (PD) patients indicate that pramipexole (Mirapexin(R) ...
